2022 Help me understand this report
All anti-CD20 monoclonal antibodies have similar efficacy and safety risks: Yes
Search citation statements
Paper Sections
Select...
Citation Types
0
1
0
Year Published
2022
2024
Publication Types
Select...
1
1
Relationship
0
2
Authors
Journals
Cited by 2 publications
(1 citation statement)
References 7 publications
0
1
0
“…In their essays, Cree 4 and Sellebjerg 5 present compelling arguments for and against anti-CD20 monoclonal antibodies having similar efficacy and risks. One author cites similar clinical efficacy and safety after CD20 depletion is completed, and the second cites studies that evaluate the safety, effectiveness of individual monoclonal antibodies (mAbs), and animal studies showing differences.…”
mentioning
confidence: 99%
“…In their essays, Cree 4 and Sellebjerg 5 present compelling arguments for and against anti-CD20 monoclonal antibodies having similar efficacy and risks. One author cites similar clinical efficacy and safety after CD20 depletion is completed, and the second cites studies that evaluate the safety, effectiveness of individual monoclonal antibodies (mAbs), and animal studies showing differences.…”
mentioning
confidence: 99%
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
